On February 27, 2023 Biocure Technology Corp. (CSE:CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") reported that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued 96,404 shares at $11.45 CAD per share for gross proceeds of $1,103,749 (Press release, Biocure Technology, FEB 27, 2019, View Source,-korea-bpk-announces-closing-of-private-placement [SID1234628756]). After the issuance of new BPK shares, CURE holds now 97.32% interest in BPK.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The net proceeds from the non-brokered private placement are intended to be used for general working capital and research and development.